glp1versus

Foundayo vs Saxenda

orforglipron (GLP-1 receptor agonist (oral small-molecule)) vs liraglutide (GLP-1 receptor agonist) — a complete side-by-side comparison.

Eli Lilly and CompanyNovo Nordisk

Foundayo weight loss

12.4%

Saxenda weight loss

8%

Foundayo dosing

Once daily

Saxenda dosing

Once daily

Reviewed by Dr. Elena Vance, DOLast reviewed 7 sources cited

Quick Summary

Foundayo (orforglipron) and Saxenda (liraglutide) are both glp-1 receptor agonist (oral small-molecule)s. In clinical trials, Foundayo showed greater weight loss (12.4% vs 8%).

See the comparison table below for detailed side-by-side data.

Foundayo vs Saxenda: Full Comparison

FeatureFoundayo(orforglipron)Saxenda(liraglutide)
Active Ingredientorforglipronliraglutide
Drug ClassGLP-1 receptor agonist (oral small-molecule)GLP-1 receptor agonist
ManufacturerEli Lilly and CompanyNovo Nordisk
FDA Approved2026-04-012014-12-23
Approved Indications
  • Chronic weight management in adults with obesity (BMI >=30 kg/m^2), or overweight (BMI >=27 kg/m^2) with at least one weight-related comorbid condition, as an adjunct to a reduced-calorie diet and increased physical activity
  • Chronic weight management in adults with BMI ≥30 or ≥27 with at least one weight-related comorbidity
  • Chronic weight management in patients aged 12-17 with body weight >60 kg and BMI corresponding to ≥30 kg/m² for adults
Routeoralsubcutaneous injection
FrequencyOnce dailyOnce daily
Starting Dose3 mg once daily0.6 mg daily
Maintenance Dose12 mg or 36 mg once daily3.0 mg daily
Max Dose36 mg once daily3.0 mg daily
Weight Loss (%)12.4%8%
A1C ReductionN/A (not indicated for diabetes)N/A (not indicated for diabetes)
Key TrialATTAIN-1 (72 weeks)SCALE Obesity and Prediabetes (56 weeks)
List PricePricing announced at U.S. launch (April 2026); confirm with LillyDirect$1,349/month
With InsuranceFormulary coverage evolving; many commercial plans expected to require prior authorization$25-$250/month (varies; weight-loss coverage is limited)
Savings CardEli Lilly savings program details emerging via LillyDirect$25/month (Novo Nordisk savings card, eligible patients)

Side Effects: Foundayo vs Saxenda

Side EffectFoundayoSaxenda
Nausea21-27%39%
Diarrhea15-20%21%
Vomiting10-16%16%
Constipation8-14%19%
Indigestion/dyspepsia6-10%Not reported
Abdominal pain5-9%5%
Headache5-8%14%
Fatigue4-7%8%
Hair loss3-5%Not reported
Pancreatitis (rare)<0.5%<1%
Decreased appetiteNot reported10%
DyspepsiaNot reported10%
DizzinessNot reported7%
Gallbladder eventsNot reported2.5%

Severity scale: 1 (mild) to 5 (serious). Based on FDA prescribing information and clinical trial data.

Related Comparisons

Foundayo vs OzempicSaxenda vs OzempicFoundayo vs WegovySaxenda vs WegovyFoundayo vs MounjaroSaxenda vs MounjaroFoundayo vs ZepboundSaxenda vs Zepbound

Frequently Asked Questions

Sources & References

FDA & Regulatory

  1. Foundayo FDA Drugs@FDA approval record — FDA
  2. Saxenda FDA Drugs@FDA approval record — FDA

Clinical Trial Records

  1. ATTAIN-1 clinical trial record — ClinicalTrials.gov
  2. SCALE Obesity and Prediabetes clinical trial record — ClinicalTrials.gov

Peer-Reviewed Literature

  1. Pi-Sunyer X et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management (SCALE Obesity and Prediabetes). N Engl J Med 2015;373:11-22 — New England Journal of Medicine

Manufacturer Information

  1. Saxenda patient and healthcare provider website — Novo Nordisk

Reference Entries

  1. Liraglutide entry on Wikipedia — Wikipedia

This content is for informational purposes only and is not medical advice. Always consult your healthcare provider before making medication decisions. See our full medical disclaimer.